Clinical / R&D
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
A goal of "Precision Panc" in the UK and US-based "Precision Promise" is to create a knowledge bank of integrated data for the development of bespoke personalized treatments for pancreatic cancer patients.
Amgen walks through its price-setting model for PCSK9 inihibitor Repatha and says new outcomes data just presented at ACC provides more evidence that "prices that exist in the market are indeed value-based."
FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.
Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.
Payers and prescribers, not just the US FDA, need to understand the basis of approval, John Rex says.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.